AzTrials
AzTrials

AutismNCT00319722

EEG Studies of Sensory Processing in Autistic Children

An observational study of Autism, run by Massachusetts General Hospital at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study uses EEG to study brain waves at rest and in response to specific auditory and visual sensory stimuli in autistic children. We hypothesize that, compared to same age peers, autistics will show abnormalities in their electrophysiologic processing of sounds (tones and phonemes)and visual stimuli (flashes of… Read more about this study

Who is it for?
Ages 3 months to 8 yearsHealthy volunteers can take part
Conditions the study is for
Autism
How many people
130 participants
Where
1 siteUnited States
Study dates
Feb 2006to Mar 2011
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 months to 8 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: autistic children meeting criteria for autism based on ADOS and ADI and clinical DSM IV or their siblings between the ages of 3 months to 13 years.

Who may be able to join

  • autistic children or their younger siblings between the ages of 3 months to 8 year
  • Controls: typically developing children 3mo to 8 years without known language or social disorder and not related to child with autism
  • Exclusion Criteria: progressive encephalopathy, treatment with multiple antiepileptic drugs, known genetic diagnosis.
  • -

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Alyssa Orinstein contact

617-966-9766

transcend@partners.org

United States1 site, 1 recruiting
  • MGH LADDERS Clinic

    Lexington, Massachusetts, 02421

    Katherine M. Martien, M.D., 781-860-1720, kmartien@partners.org

    Katherine M. Martien, M.D.

    Recruiting

Other trials in United States

About this study

Official title: Electrophysiologic Indicators of Gating and Timing Abnormalities in Autism

This study uses EEG to study brain waves at rest and in response to specific auditory and visual sensory stimuli in autistic children. We hypothesize that, compared to same age peers, autistics will show abnormalities in their electrophysiologic processing of sounds (tones and phonemes)and visual stimuli (flashes of light)and that these abnormalities will be able to separate autistics not only from typical children but also into clinical subgroups with specific biological/electrophysiological characteristics. We hope to find biological measures which will prove diagnostic of autism in very young children and which can be used in the measurement of treatment outcome in future intervention trials.

Read the detailed description

Specific Aims:

Aim 1: To recruit 75 children with autism and 75 age- and sex-matched controls ages 6 to 8 years old for an electrophysiological study and to characterize the subjects using appropriate instruments for autism diagnosis, language functioning and behavior/sensory profile, and to measure head circumferences Aim 2: To acquire and analyze event-related potential (ERP) data in the auditory and visual modality.

ERP Hypothesis: Increased amplitude, altered morphology, impaired temporal discrimination and delayed responsiveness will be found early in the processing hierarchy, and the severity of these abnormalities will be associated with the severity of dysfunction at higher levels of cortical processing.

Aim 3: To acquire EEG data and to analyze it quantitatively. Quantitative EEG Hypothesis: Both interhemispheric and intrahemispheric coherence measures of the EEG will be significantly deviant from those in the normal sample and predicted by abnormalities of ERPs. In addition, EEG background alpha activity will show post mature (i.e. higher) frequencies (Hz) than would be expected for age and focal epileptiform activity and slowing (i.e. paroxysmal theta) will predict dysfunction on the ERPs.

Rationale:

The goal of this grant is to use electrophysiological measures to characterize abnormalities in gating and timing in the autistic brain. The motivation for this research project derives from findings and models in autism of increased excitation/inhibition ratios, increased brain and white matter volume and altered connectivity. These changes, alone and in combination, have the potential to alter the intensity, timing and integration of signaling at multiple stages of processing. These signaling problems can potentially lead to the autistic behavioral phenotype through cognitive processing abnormalities including the hyperspecificity/overselectivity of autism, as well as to such features of autism as sensory processing abnormalities, seizures, and anxiety. We believe that characterizing abnormalities related to gating and timing phenomena may lead to the development of an electrophysiological battery that can be utilized for early diagnosis, prognosis and subtyping of autism, as well as the tracking of treatment efficacy.

Subjects:

Subjects will be recruited from the general population, the Ladders Clinic at MGH/Spaulding Hospital, where the PI, Dr. Martien, is employed as a clinician, as well as from the clinical practice of Dr. Herbert at the MGH-Institute of Health Professions preschool clinic. Flyers will be placed on available bulletin boards at the two clinics and throughout the greater Boston area, particularly at all Partners, Harvard, MIT, hospital, clinic, research, and educational settings.

The study will seek to enroll eighty 75, 6 to 8 year olds with autism and 75 age and sex matched controls. Children will be considered for inclusion in the autism group if:

  • English is the primary language in the home
  • Experimental group: Child meets criteria for autism on the ADI-R and ADOS evaluation scales (this inclusion criteria will be explained during the consent process).

They meet non of the Exclusionary criteria, which include:

  • Known genetic disorder
  • Hearing or gross sensorimotor deficits
  • Clinical evidence of progressive encephalopathy
  • Asphyxia at birth or any other time
  • Frequent seizures or use of anticonvulsant drugs or psychotropic medication
  • Known presence of focal brain lesions, brain atrophy or ventriculomegaly. Children will be considered for the control group if the child meets all of the above criteria except they do not meet the criteria for autism or close to it on the ADOS and ADI-R evaluation scales.

Methods:

The child will be seated in a comfortable chair and the physiological assessment will begin after a head circumference is obtained with a tape measure, an EEG cap is placed on the child's head and gel is applied to each electrode in the cap. The tasks include 5 minutes of baseline EEG recording while the child is looking at a design on a monitor placed 2 meters in front of the chair. We then will proceed with a series of auditory and visual stimuli presented by computer through two speakers placed 1 meter in front of the child (auditory) and strobe (visual) at 50 cm. The paradigms will include a presentation of pairs of tones with variable interstimulus intervals presented in random order at 65 dB SPL, a paradigm with either 1000 Hz or 800 Hz at 65 dB, and a final auditory paradigm with two different phonemes, presented at 65 dB. The visual tasks will involve the presentation of flashes of light which vary in frequency and luminance both reflected off a white board one meter from the child and directly at the child's visual field. In each series, there will be a 1 minute break between two blocks of 100 trials each for a total of 200 trials. The experimenter will show the child an interesting toy and talk to the child during the break.

The parent will be asked to complete the Vineland Adaptive Behavior Scales, the Communication and Symbolic Behavior Scales (CSBS) and the MacArthur Communicative Development Inventory. In the case that the subjects are recruited from the Ladders infant sib study, we will use the existing ADI-R and ADOS data because Ladders has authorized the release of this information.

The total time for the laboratory session will be approximately 1 hour. The full battery of tasks will be performed on compliant children. For those children whose attention cannot be maintained for the full battery, the examiner will stop and give breaks as needed. The examiner will go on to the next task or terminate the session if the subject or parent of the subject chooses to do so.

Conditions
Autism
Keywords
autism, pervasive developmental disorder, evoked potentials, EEG, Coherence
Medical subject headings
Autistic Disorder, Child Development Disorders, Pervasive

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. EEG and ERP abnormalities

    Measured: 2 years

Secondary outcomes (1)
  1. Characteristic and severity of autistic behaviors

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2006 (estimated)
  2. Study startFeb 2006
  3. Primary completionMar 2011 (estimated)
  4. Study completionMar 2011 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
130 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00319722
Sponsor's protocol ID
2005-P-000868/3
Status last verified
May 2010
First submitted
27 Apr 2006
Last updated
4 May 2010
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Autism, run by Massachusetts General Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 May 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Alyssa Orinstein (617-966-9766, transcend@partners.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

EEG and ERP abnormalities (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in